|XDATA – October 9th 2015|
|Rheonix disclosed selling 60% of its $36.5 million non-brokered equity offering to twenty-four investors. The sale started a little over a week ago according to the document filed at the SEC. $14.64 million in additional funding can be raised before September 2016 based on the placement’s structure. The company closed four previous unregistered private placements which raised an estimated $30.52 million.|
|Rheonix commercializes the Encompass Optimum platform, a highly customizable technology offering versatility and affordability for use in research laboratories. The platform performs fully automated, complex molecular assays in an easy-to-use and economical format on the company’s CARD cartridge. The company is backed by Cayuga Venture Fund, Gefinor Ventures and Rand Capital.|
|The company is headquartered in Ithaca NY. Rheonix elected to keep its revenues undisclosed.
The executive team includes Anthony Eisenhut, Christopher Smith, Gregory Galvin and John Brenner.
The company has raised an estimated total of $52.39 million via private unregistered security offerings.
Status: First close
Industry: Other Technology
Amount offered: $36.5 million
Amount placed: $21.86 million
SEC filing: Source
First sale: 09-29-2015
Data as of: 10-09-2015
Hey if you didn’t know about it, maybe it is time to add XDATA as part of your market monitoring regimen, 14 days free trials are available here.
Change: offered +67% / raised +338% / placed 79%
SenGenix upped its financing to $2.5 million from $1.5 million after receiving new commitments. An additional $1.52 million worth of securities was placed by the company with twelve investors since the company last released data almost a year ago. This brings to $1.97 million the amount raised from the fifteen backers who subscribed to the offering. The subscription is structured to close once the 21% left is fully subscribed or in three weeks at the latest. This is the first time securities are issued by SenGenix under a registration exemption.
SenGenix markets and develops point-of-care diagnostic tests (POCT) based on fluorescently responsive sensors (FRS) that will deliver fast, accurate, actionable patient data at a low cost. The product platform is centered around a protein-engineering technology developed at Duke University Medical Center. The company plans on rolling out a stand-alone Creatinine test, and a Basic Metabolic Panel (BMP) consisting of the eight most commonly ordered tests which are Glucose, BUN, Creatinine, Sodium, Potassium, Calcium, Chloride and Bicarbonate.
The company, headquartered in Durham NC, was registered in 2012. SenGenix kept its revenues undisclosed.
The executive team includes Richard S Surwit and Sandra Cummings.
The board of directors includes Homme Hellinga, Lawrence Cohen and Ralph Snyderman.
Status: Intermediary close
Amount offered: $2.5 million
Amount placed: $1.97 million
First sale: 08-02-2013
Data as of: 07-07-2014
|MetaStat disclosed selling 36% of its non-brokered mezzanine financing. The company launched a $600,000 investment round subscribed so far by six investors. The subscription which raised $215,000 started one month ago. The offering will remain open until May 2015 while an additional $385,000 worth of securities is sold to investors. A total of five unregistered securities offerings closed by the company raised an estimated $15 million.
MetaStat trades under symbol OTC: MTST
|The company is a development stage life sciences organization that develops and commercializes diagnostic products and novel therapeutics for the early and prediction and treatment of systemic metastasis – cancer that spreads from a primary tumor through the bloodstream to other areas of the body.|
|The company is headquartered in Montclair NJ. MetaStat kept its revenues undisclosed.
The executive team includes Daniel Schneiderman, Oscar Bronsther and Warren Lau.
The board of directors includes David Epstein, David Siegel, Johan (thijs) Spoor and Patrick Mooney.The company has raised an estimated total of $15.22 million via private unregistered security offerings.
Status: First close
Amount offered: $600,000
Amount placed: $215,000
First sale: 05-22-2014
Data as of: 06-20-2014
Lumacyte disclosed selling 2% of its $2 million non-brokered financing round to one investor. According to the filing, $30,000 worth of equity was subscribed a little over a week ago. An additional $1.97 million in funding is to be raised until the offering draws to a close in April 2015. The equity offering’s expected net proceeds will amount to $1.9 million which excludes $100,000 to be paid toward officers’ salaries. This is the first time Lumacyte is selling securities under a registration exemption.
The company developed and produces microfluidic and optics based instruments and sub-components that enable cell biologists, biomedical researchers, pharmaceutical and biotechnology companies to characterize, select, and sort mammalian cell samples without the use of antibody labels.
Sean J Hart (CEO) leads the Keswick VA based company which was registered in 2012. Revenues on or below $1 million were reported by Lumacyte.
The executive team includes Sean Jeffrey Hart.
The board of directors includes Renee Adele Hart.
Status: First close
Amount offered: $2 million
Amount placed: $30,000
First sale: 04-30-2014
Data as of: 05-09-2014
Diomics raised $1.1 million as part of a fully subscribed non-brokered equity offering. The subscription, which started on April 15th, lured five investors. No offering was previously initiated by the company under a registration exemption with the SEC.
The company commercializes a technology platform, called Diomat, which picks up biologic materials from a variety of surfaces and release the majority of the DNA from the sample into an extraction solution with little or no sample retained with the capture matrix. The company developed its first product, the X-Swab, designed for forensic and diagnostic applications.
The company, headquartered in Carlsbad CA, is led by John Steel (President and CEO). Diomics elected to keep its revenues undisclosed.
The board of directors includes James Woodcock, Kevin Butler, Kirk Avery, Paul Buss and William Ballard.
Amount offered: $1.1 million
Amount placed: $1.1 million
First sale: 04-15-2014
Data as of: 04-21-2014
Enumeral Biomedical disclosed selling 85% of its non-brokered mezzanine financing. The company launched a $750,000 investment round subscribed so far by six investors. The subscription which raised $640,000 started a week ago. According to the offering’s structure the company may raise an additional $120,000 until February 2015. The company closed three unregistered private placements which raised an estimated $6.34 million.
The company commercializes a proprietary microengraving technology that provides rapid and simultaneous analysis of antibody affinity and specificity as well as cytokine profiles and T-cell functionality. The technology is designed for the diagnosis and treatment of infectious, autoimmune and inflammatory diseases.
The company, headquartered in New York NY, is led by Arthur H. Tinkelenberg (President). Enumeral Biomedical kept its revenues undisclosed. The executive team Derek Brand and John J. Rydzewski. The board of directors includes Allan Rothstein, Barry Buckland, Daniel B. Wolfe, Emanuele Ostuni and Michael Weiss.
Status: First close
Company: Enumeral Biomedical
Amount offered: $750,000
Amount placed: $640,000
First sale: 2014-02-03
VentriPoint Diagnostics, Ltd., formerly known as Luca Capital Inc., completed a $748,000 offering of 12% non-convertible secured debentures (debentures) due July 18, 2014 with one investor. This investor is most likely BluMont Innovation PE Strategy Fund I, a fund managed by BluMont Capital. The company is trading on the TSX Venture Exchange (Canada) and over the counter (OTC) in the US. The company trades under the symbols VPT and VPTDF, its last trading price was $0.09 on both exchanges which sets its market capitalization at around CAD$12.75 million. The stock traded between CAD$0.08 and 0.16 over the last fifty-two weeks. The debentures are secured by a general security agreement against substantially all of the assets of the company’s wholly-owned subsidiary, VentriPoint, Inc., including its intellectual property, as a first charge. All debentures rank equally with one another. Further details on the debentures can be found in the press release.
This non-brokered private placement is the first of two previously announced financing events. The company expects to place USD$1 million worth of units. Each unit will consist of USD$1,100 principal amount of 3 year non-convertible secured debentures and 2,000 common shares.
VentriPoint designed and markets diagnostic tools to monitor patients with heart disease. Its main product, Angelo VMS, is a 2D ultrasound diagnostic tool for measuring right ventricle heart function. The company has a suite of applications for all major heart diseases and imaging modalities including congenital heart disease, left or right heart failure and normal hearts. VMS has been cleared for clinical use in Canada and Europe, it is currently waiting for FDA clearance in the US.
The company had insignificant revenues amounting to $374,000 for the year ending on December 31st 2012. VentriPoint, founded by Florence H. Sheehan (CSO – Chief Scientist Officer), is registered in Canada with headquarters in Seattle, WA. The company is lead by George Adams (CEO), Ellen Briant (CFO), Amol Karnick (VP – Sales), Scott Ashley (VP – R&D) and Eyal Schwartz (Chief Architect).